News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
195,816 Results
Type
Article (19563)
Company Profile (111)
Press Release (176142)
Section
Business (63910)
Career Advice (810)
Deals (9046)
Drug Delivery (70)
Drug Development (18828)
Employer Resources (138)
FDA (3319)
Job Trends (5989)
News (95270)
Policy (7048)
Tag
Academia (1487)
Alliances (17277)
Alzheimer's disease (491)
Antibody-drug conjugate (ADC) (47)
Approvals (3289)
Artificial intelligence (77)
Bankruptcy (48)
Best Places to Work (4856)
Biosimilars (40)
Biotechnology (67)
Breast cancer (42)
Cancer (358)
Cardiovascular disease (42)
Career advice (713)
Cell therapy (94)
Clinical research (13997)
Collaboration (198)
COVID-19 (973)
C-suite (58)
Data (364)
Diabetes (46)
Diagnostics (2310)
Earnings (14322)
Employer resources (118)
Events (28968)
Executive appointments (169)
FDA (3463)
Funding (173)
Gene therapy (72)
GLP-1 (286)
Government (1307)
Healthcare (4915)
Infectious disease (1015)
Inflammatory bowel disease (45)
Interviews (112)
IPO (3599)
Job creations (1314)
Job search strategy (630)
Layoffs (144)
Legal (1178)
Lung cancer (63)
Management (41)
Manufacturing (86)
Medical device (2575)
Medtech (2579)
Mergers & acquisitions (5536)
Metabolic disorders (155)
Neuroscience (600)
NextGen Class of 2024 (2087)
Non-profit (1671)
Northern California (502)
Obesity (102)
Opinion (96)
People (26644)
Phase I (4139)
Phase II (5804)
Phase III (5566)
Pipeline (124)
Postmarket research (561)
Preclinical (2360)
Press Release (61)
Radiopharmaceuticals (60)
Rare diseases (75)
Real estate (2510)
Recruiting (53)
Regulatory (4926)
Research institute (1257)
Resumes & cover letters (106)
Southern California (318)
Startups (1993)
United States (4133)
Vaccines (172)
Weight loss (84)
Date
Today (35)
Last 7 days (105)
Last 30 days (924)
Last 365 days (11668)
2024 (10913)
2023 (13055)
2022 (15628)
2021 (17774)
2020 (16400)
2019 (15053)
2018 (10873)
2017 (10379)
2016 (10251)
2015 (10966)
2014 (8010)
2013 (6932)
2012 (7359)
2011 (7533)
2010 (7020)
Location
Africa (328)
Arizona (54)
Asia (11122)
Australia (1941)
California (989)
Canada (400)
China (83)
Colorado (55)
Connecticut (45)
Europe (28594)
Florida (132)
Illinois (95)
Indiana (89)
Maryland (131)
Massachusetts (826)
Michigan (65)
Minnesota (86)
New Jersey (322)
New York (383)
North Carolina (242)
Northern California (502)
Ohio (46)
Pennsylvania (164)
South America (398)
Southern California (318)
Texas (139)
Washington State (86)
195,816 Results for "gilead sciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Gilead and Kite Are Cutting Employees, Closing Seattle, Philadelphia Sites
Gilead’s layoffs include 72 employees at its Seattle location, which will close. Kite will shut down its Philadelphia facility. The layoffs are attributed to aligning resources with long-term strategic goals.
November 15, 2024
·
2 min read
·
Angela Gabriel
Antibody-drug conjugate
Gilead Plots ADC Comeback With Potential $415M License Agreement
The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder cancer and its late-stage fail in NSCLC.
December 3, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Gilead Sciences to Present at Upcoming Investor Engagements
November 11, 2024
·
1 min read
Earnings
Gilead Beats Q3 Expectations Fueled by HIV Drug Sales, Raises Full-Year Guidance
BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and “steady,” while noting the company continues to demonstrate “reliable strength” in its human immunodeficiency virus business.
November 7, 2024
·
3 min read
·
Tristan Manalac
Infectious disease
Gilead Partners With Generics Developers to Provide HIV Drug to Low-Income Countries
Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for treating human immunodeficiency virus in heavily pre-treated adults with multidrug-resistant infections.
October 3, 2024
·
2 min read
·
Tristan Manalac
Bladder Cancer
Gilead Withdraws ADC Trodelvy in Bladder Cancer After Trial Failure
The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for bladder cancer in 2021, failed its confirmatory trial earlier this year.
October 18, 2024
·
2 min read
·
Annalee Armstrong
Infectious disease
GSK, ViiV Tout 99% Effectiveness for Long-Acting HIV PrEP as Gilead Gains Ground
Real-world evidence show that GSK and ViiV Healthcare’s long-acting pre-exposure prophylaxis Apretude can prevent nearly all HIV infections, while rival Gilead Sciences is moving quickly toward an approval for a twice-yearly option.
October 17, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Gilead Sciences Announces Third Quarter 2024 Financial Results
November 7, 2024
·
20 min read
Approvals
Gilead’s $4.3B Bet on CymaBay Pays Off With FDA Nod for Autoimmune Liver Disease Drug
The regulator’s approval of Livdelzi for primary biliary cholangitis under the accelerated pathway is a boost to Gilead Sciences’ liver disease business. Analysts expect the drug to reach more than $1 billion in sales.
August 15, 2024
·
2 min read
·
Tristan Manalac
Infectious disease
Gilead Touts 96% HIV Risk Reduction With Twice-Yearly PrEP, Eyes Regulatory Filings
Armed with readouts from the PURPOSE 1 and 2 trials, Gilead Sciences is now gearing up for global regulatory submissions for lenacapavir as a pre-exposure prophylactic option for human immunodeficiency virus.
September 13, 2024
·
2 min read
·
Tristan Manalac
1 of 19,582
Next
